Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

Voncina, L. and Godman, B. B. and Vlahovic-Palcevski, V. and Bennie, M. and Bishop, I. (2011) Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future. Pharmacoepidemiology and Drug Safety, 20 (Suppl.). S210-S210. 482. ISSN 1053-8569 (https://doi.org/10.1002/pds.2206)

Abstract

Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

• Share and Export
  

  RDF+XMLBibTeXRIOXX2 XMLRDF+N-TriplesJSONDublin CoreAtomSimple MetadataReferMETSHTML CitationASCII CitationOpenURL ContextObjectEndNoteOpenURL ContextObject in SpanMODSMPEG-21 DIDLEP3 XMLData Cite XMLRIS (EndNote Online, Zotero, Ref manager, etc)RDF+N3Multiline CSV
• Item metadata

  Item type:	Article
  ID code:	41433
  Dates:	Date Event 2011 Published
  Subjects:	Medicine > Pharmacy and materia medica
  Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
  Depositing user:	Pure Administrator
  Date deposited:	13 Oct 2012 15:59
  Last modified:	08 Apr 2024 20:09
  URI:	https://strathprints.strath.ac.uk/id/eprint/41433